Reviewer's report

Title: Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

Version: 3 Date: 11 April 2015

Reviewer: Junji Tsurutani

Reviewer's report:

Dell'Ova et al reported several clinicopathological variables as prognostic and predictive values in a multicenter-retrospective study on patients with advanced breast cancer treated with eribulin, but there exists limitation of interpretation on predictive value due to lack of comparison with no eribulin use. So, three factors they found are clearly prognostic in the study population, but not prognostic.

Minor points are as follows.
1. Line 99, reference 3 does not correspond to what authors describe here.
2. From line 173 to 176, what is "cure"? Also, even if patients with one cycle of treatment, they should be incorporated in the analysis. Otherwise, the study suffers selection bias.
3. Line 210 and 211, what is "cure"?

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests